SCHEMBL4163472

SCHEMBL4163472

CS(=O)(=O)NNCCCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4430993 0.76
SCHEMBL9749128 0.74
SCHEMBL1504574 0.72
Hydrochloric Acid SCHEMBL3523504 0.72 KDM4E (0.33)
SCHEMBL8498999 0.69
SCHEMBL8514969 0.65
SCHEMBL2582338 0.63
SCHEMBL249233 0.63
SCHEMBL7737717 0.62
SCHEMBL21357711 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110914297-B Anti-human interleukin 2 antibody and use thereof 基础科学研究院 2023-06-06 CN disclosed
CN-110914297-A Anti-human interleukin-2 antibody and application thereof 基础科学研究院 2020-03-24 CN disclosed
CN-102210698-A Use of composition containing 3-aminopyridine-2-formaldehyde thiosemicarbazone in treatment of cancers VION PHARMACEUTICALS INC 2011-10-12 CN disclosed
EP-1804816-A4 COMBINATION THERAPY COMPRISING CLORETAZINE(TM) VION PHARMACEUTICALS INC (US) 2009-07-01 EP disclosed
CN-100427139-C Water-soluble shps as novel alkylating agents VION PHARMACEUTICALS INC (US) 2008-10-22 CN disclosed
CN-101014353-A Combination therapy comprising cloretazine(tm) VION PHARMACEUTICALS INC (US) 2007-08-08 CN disclosed
EP-1804816-A2 COMBINATION THERAPY COMPRISING CLORETAZINE(TM) Vion Pharmaceuticals, Inc. (US) 2007-07-11 EP disclosed
CN-1805752-A Water-soluble shps as novel alkylating agents VION PHARMACEUTICALS INC (US) 2006-07-19 CN disclosed
WO-2005094282-A2 COMBINATION THERAPY COMPRISING CLORETAZINETM VION PHARMACEUTICALS, INC. (US) 2005-10-13 WO disclosed
CN-1555798-A Cancer treatment comprising 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 维奥恩药品公司 2004-12-22 CN disclosed
CN-1176067-C Anti-tumor 2-amino-carboyl-1,2-di (methylsulfonyl)-1-(substituted) diazane Ү³��ѧ 2004-11-17 CN disclosed
CN-1124846-C N, N' -bis (sulfonyl) hydrazines as antitumor agents UNIV YALE (US) 2003-10-22 CN disclosed
CN-1405152-A Anti-tumor 2-amino-carboyl-1,2-di (methylsulfonyl)-1-(substituted) diazane UNIV YALE (US) 2003-03-26 CN disclosed
CN-1095828-C Antitumor 2-aminocarbonyl-1, 2-bis (methylsulfonyl) -1- (substituted) hydrazines UNIV YALE (US) 2002-12-11 CN disclosed
CN-1278169-A N, N' -bis (sulfonyl) hydrazines as antitumor agents UNIV YALE (US) 2000-12-27 CN disclosed
CN-1191482-A Antitumor 2-aminocarbonyl-1, 2-bis (methylsulfonyl) -1- (substituted) hydrazines UNIV YALE (US) 1998-08-26 CN disclosed
EP-0541322-A1 1-Alkyl-2-acyl-1,2-disulfonylhydrazines with antineoplastic activity YALE UNIVERSITY (US) 1993-05-12 EP disclosed